[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336120-105":59,"doc-detail-336120-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-influence-of-gleason-score-6-histology-on-the-outcome-of-high-risk-localized-prostate-cancer-after-modern-radiotherapy","The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapy","","The study retrospectively evaluates how Gleason score ≤ 6 histology influences outcomes in high-risk localized prostate cancer treated with modern radiotherapy. Outcomes from 1374 patients were analyzed, comparing high-risk low grade (Gleason ≤6) versus high-risk high grade (Gleason ≥7), with additional subgroup analyses by treatment modality including brachytherapy (HDR/LDR with or without EBRT) and modern external beam radiotherapy (IMRT or SBRT). At median follow-up of 60 months, 5-year biochemical failure-free survival was higher for the Gleason ≤6 group (97.8% vs 91.8%), with lower clinical failure (0% vs 5.4%) and improved distant metastasis-free survival (100% vs 96.0%).",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-influence-of-gleason-score-6-histology-on-the-outcome-of-high-risk-localized-prostate-cancer-after-modern-radiotherapy/336120/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-influence-of-gleason-score-6-histology-on-the-outcome-of-high-risk-localized-prostate-cancer-after-modern-radiotherapy/336120.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main aim of the study regarding Gleason score ≤ 6?","Question",{"text":112,"@type":113},"To retrospectively review outcomes in high-risk localized prostate cancer patients with Gleason score ≤ 6 after modern radiotherapy, comparing them with higher Gleason score groups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the patient groups defined?",{"text":117,"@type":113},"Patients were divided into high-risk low grade (HRLG: Gleason score ≤ 6) and high-risk high grade (HRHG: Gleason score ≥ 7), based on their Gleason score.",{"name":119,"@type":110,"acceptedAnswer":120},"What radiotherapy approaches were included?",{"text":121,"@type":113},"The study included brachytherapy with or without EBRT (HDR-BT and combined LDR-BT data) as well as modern EBRT using intensity-modulated radiotherapy (IMRT) or stereotactic body radiotherapy (SBRT).",{"name":123,"@type":110,"acceptedAnswer":124},"What outcomes differed most between HRLG and HRHG?",{"text":125,"@type":113},"The HRLG group showed better 5-year biochemical failure-free survival, no observed clinical failures, and improved 5-year distant metastasis-free survival compared with the HRHG group.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336120,1790159709,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe influence of Gleason score ≤ 6 histology on the outcome of high‑risk localized prostate cancer after modern radiotherapy  \nHideya Yamazaki1*, Gen Suzuki1, Koji Masui1, Norihiro Aibe1, Takuya Kimoto1, Kei Yamada1, Koji Okihara2, Fumiya Hongo2, Masayoshi Okumi2, Takumi Shiraishi2, Atsuko Fujihara2, Ken Yoshida3, Satoaki Nakamura 3, Takashi Kato4, Yasutoshi Hashimoto4 & Haruumi Okabe4  \nWe aimed to retrospectively review outcomes in patients with high‑risk prostate cancer and a Gleason score ≤ 6 following modern radiotherapy. We analyzed the outcomes of 1374 patients who had undergone modern radiotherapy, comprising a high‑risk low grade [HRLG] group (Gleason score ≤6; n = 94) and a high‑risk high grade [HRHG] group (Gleason score ≥7, n = 1125). We included 955 patients who received brachytherapy with or without external beam radio‑therapy (EBRT) and 264 who received modern EBRT (intensity‑modulated radiotherapy [IMRT] or stereotactic body radiotherapy [SBRT]). At a median follow‑up of 60 (2–177) months, actuarial 5‑year biochemical failure‑free survival rates were 97.8 and 91.8%(p = 0.017), respectively. The frequency of clinical failure in the HRLG group was less than that in the HRHG group (0% vs 5.4%, p = 0.012). The HRLG group had a better 5‑year distant metastasis‑free survival than the HRHG group (100% vs 96.0%, p= 0.035). Asthe HRLG group exhibited no clinical failure and better outcomes than the HRHG group, the HRLG group might potentially be classified as a lower‑risk group.  \nKeywords Prostate cancer, High-dose-rate brachytherapy, Low-dose-rate brachytherapy, Intensity modulated radiotherapy, Stereotactic body radiotherapy, Gleason score  \nProstate cancer is the most diagnosed malignancy among men in Western countries1. In 2021, approximately 248,530 new cases of prostate cancer were diagnosed in the United States, accounting for 10.7% of cancer-related deaths1. Prostate-specific antigen (PSA) screening systems have facilitated its early detection. Low-grade (Gleason score ≤ 6) prostate cancer, the most common subgroup1–4, may not threaten life expectancy in general, while overtreatment, which can induce unnecessary side-effects, might affect quality of life and substantially increase healthcare costs4. To reduce the risk of overtreatment, active surveillance (AS) has been introduced as a standard of care for patients with low-risk prostate cancer and a life expectancy of ≥ 10 years1.  \nSome studies have suggested that prostate cancers with a Gleason score of ≤ 6 should be considered as noncancerous lesions that need not be treated4–6, while other studies have not supported this suggestion7–9 given the pathological, surgical, and radiotherapeutic aspects involved in diagnosing and treating such patients10–13. To our knowledge, few studies have focused on outcome data in relation to high-risk patients with a Gleason score ≤ 6 following radiotherapy using advanced technology, namely, intensity modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and/or brachytherapy (BT) using higher prescribed doses sufficient to meet modern radiotherapy criteria1.  \nDose escalation has been shown to improve biochemical control in patients with localized prostate cancer14–17, and the National Comprehensive Cancer Network guidelines recommend doses > 70 Gy in conventional fractions1. Therefore, we examined the role of a Gleason score ≤ 6 in patients with high-risk prostate cancer treated with modern radiotherapy (IMRT) using a high dose and/or advanced technology (SBRT or BT) .  \n1Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, Kyoto 602-8566, Japan. 2Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. 3Department ","cbCaijxPV2txkuoA","https://ap.wps.com/l/cbCaijxPV2txkuoA","pdf",1028276,"English","# Materials and methods\n## Patients","[{\"question\":\"What is the main aim of the study regarding Gleason score ≤ 6?\",\"answer\":\"To retrospectively review outcomes in high-risk localized prostate cancer patients with Gleason score ≤ 6 after modern radiotherapy, comparing them with higher Gleason score groups.\"},{\"question\":\"How were the patient groups defined?\",\"answer\":\"Patients were divided into high-risk low grade (HRLG: Gleason score ≤ 6) and high-risk high grade (HRHG: Gleason score ≥ 7), based on their Gleason score.\"},{\"question\":\"What radiotherapy approaches were included?\",\"answer\":\"The study included brachytherapy with or without EBRT (HDR-BT and combined LDR-BT data) as well as modern EBRT using intensity-modulated radiotherapy (IMRT) or stereotactic body radiotherapy (SBRT).\"},{\"question\":\"What outcomes differed most between HRLG and HRHG?\",\"answer\":\"The HRLG group showed better 5-year biochemical failure-free survival, no observed clinical failures, and improved 5-year distant metastasis-free survival compared with the HRHG group.\"}]","The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapy | PDF",1790013644,23]